glp-1 dopamine The Shift: Why Food and Rewards Feel Different glp 1 dopamine GLP-1 meds

In clinical trials, individuals using semaglutide reported an average weight loss of around 15% of their body weight over 68 weeks, while tirzepatide users experienced reductions as high as 20% in some studies

Aging Population in Europe: Europe's population is increasingly aging, contributing to an increased incidence of type 2 diabetes and related illnesses

Food and beverage companies, faced with growing pressure from the increased accessibility of appetite-suppressing pills, are reformulating around the GLP-1 consumer who eats less but cares more about protein, fiber and how food makes them feel there is even now more protein in your Pop-Tarts

In this lab experiment, scientists looked at how the drug semaglutide affects muscle cells that have been made resistant to insulin, similar to what happens in type 2 diabetes

A lower price can still feel expensive if it doesn't address body weight drivers, or if the person later has to pay separately for medical services